NCT06104631View on ClinicalTrials.gov

A Prospective Trial in Patients With Crohn's Disease in Remission and Having Irritable Bowel Syndrome-like Symptoms

NARecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

March 12, 2024

Primary Completion Date

August 31, 2025

Study Completion Date

October 31, 2025

Conditions
Irritable Bowel Syndrome-like SymptomsCrohn Disease Remission
Interventions
OTHER

BK003

The product is a combination of chitin-glucan and other dietary complement components. The dosage of chitin-glucan is 3 g/day. The product is a powder for oral administration 1x/day.

OTHER

Placebo

The placebo product has the same composition in excipient, same form and same posology as BK003.

Trial Locations (2)

4000

RECRUITING

CHU Liege - Gastroenterology, Liège

59000

RECRUITING

CHU Lille - Gastroenterology, Lille

All Listed Sponsors
lead

Biokuris s.a.

INDUSTRY